Abstract
Chronic lymphocytic leukemia (CLL) is a low-grade lymphoid malignancy incurable with conventional modalities of chemotherapy. Strong and constitutive nuclear factor kappa B (NF-κB) activation is a characteristic of CLL cells. We examined the effects of a new NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on CLL cells. Dehydroxymethylepoxyquinomicin completely abrogated constitutive NF-κB activity and induced apoptosis of CLL cells. Apoptosis induced by DHMEQ was accompanied by downregulation of NF-κB-dependent antiapoptotic genes: c-IAP, Bfl-1, Bcl-XL and c-FLIP. Dehydroxymethylepoxyquinomicin also inhibited NF-κB induced by CD40 and enhanced fludarabine-mediated apoptosis of CLL cells. Results of this study suggest that inhibition of constitutive and inducible NF-κB by DHMEQ in combination with fludarabine is a promising strategy for the treatment of CLL.
This is a preview of subscription content
Access options
Subscribe to Journal
Get full journal access for 1 year
$119.00
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.






References
Keating MJ . Chronic lymphocytic leukemia. Semin Oncol 1999; 26: 107–114.
Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998; 91: 3379–3389.
Griffin J . The biology of signal transduction inhibition: basic science to novel therapies. Semin Oncol 2001; 28: 3–8.
Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572.
Capdeville R, Silberman S, Dimitrijevic S . Imatinib: the first 3 years. Eur J Cancer 2002; 38 (Suppl 5): S77–S82.
Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ . Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000; 164: 2200–2206.
Barkett M, Gilmore TD . Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 1999; 18: 6910–6924.
Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin Jr AS . NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999; 19: 5785–5799.
Pahler JC, Ruiz S, Niemer I, Calvert LR, Andreeff M, Keating M et al. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res 2003; 9: 4570–4577.
Kelley TW, Alkan S, Srkalovic G, Hsi ED . Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis. Leuk Res 2004; 28: 845–850.
Matsumoto N, Ariga A, To-e S, Nakamura H, Agata N, Hirano S et al. Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett 2000; 10: 865–869.
Ariga A, Namekawa J, Matsumoto N, Inoue J, Umezawa K . Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem 2002; 277: 24625–24630.
Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.
Andrews NC, Faller DV . A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 1991; 19: 2499.
Horie R, Watanabe T, Morishita Y, Ito K, Ishida T, Kanegae Y et al. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin–Reed–Sternberg cells. Oncogene 2002; 21: 2493–2503.
Romano MF, Lamberti A, Tassone P, Alfinito F, Costantini S, Chiurazzi F et al. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 1998; 92: 990–995.
Carew JS, Nawrocki ST, Krupnik YV, Dunner Jr K, McConkey DJ, Keating MJ et al. Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. Blood 2006; 107: 222–231.
Morales AA, Olsson A, Celsing F, Osterborg A, Jondal M, Osorio LM . High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia. Int J Cancer 2005; 113: 730–737.
Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas JA, Sanchez A, Martin-Saavedra FM et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004; 18: 1391–1400.
Tallman MS, Hakimian D . Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 1995; 86: 2463–2474.
Huang P, Sandoval A, Van Den Neste E, Keating MJ, Plunkett W . Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia 2000; 14: 1405–1413.
Acknowledgements
We thank Professor Marshall E Kadin, Harvard Medical School, for critical comments on the manuscript. This work was supported in part by Grants-in-Aid for Scientific Research from Japanese Society for Promotion of Science and Integrative Research Program of the Graduate School of Medical Sciences, Kitasato University to R Horie.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Horie, R., Watanabe, M., Okamura, T. et al. DHMEQ, a new NF-κB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells. Leukemia 20, 800–806 (2006). https://doi.org/10.1038/sj.leu.2404167
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404167
Keywords
- CLL
- NF-κB
- apoptosis
- DHMEQ
- fludarabine
Further reading
-
NF-кB inhibition by DHMEQ: in vitro antiproliferative effects on pilocytic astrocytoma and concise review of the current literature
Child's Nervous System (2020)
-
Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer
BMC Cancer (2015)
-
Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis
Cellular Oncology (2015)
-
Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells
Apoptosis (2014)
-
The novel NF-κB inhibitor IMD-0354 induces apoptosis in chronic lymphocytic leukemia
Blood Cancer Journal (2011)